Abstract Number: 5 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of PF-4var/CXCL4L1, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS)
Background/Purpose: Platelet derived chemokines, such as PF-4 and a recently isolated protein product of its nonallelic variant gene PF-4var, are implicated in several aspects of…Abstract Number: 6 • 2013 ACR/ARHP Annual Meeting
Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome
Background/Purpose: To analyse risk factors for obstetric pathology in patients with antiphospholipid syndrome (APS). To assess the effectiveness of treatment depending on pharmacotherapy. Methods:…Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta2glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β2glycoprotein I Antibodies In Systemic Autoimmune Diseases
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…Abstract Number: 12 • 2013 ACR/ARHP Annual Meeting
Phosphatidiyserine-Prothrombin Complex (aPS/PT) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome
Background/Purpose: Criteria laboratory tests for antiphospholipid syndrome (APS) include lupus anticoagulant (LAC) as well as IgG and IgM antibodies for cardiolipin and beta2 glycoprotein. Of…Abstract Number: 13 • 2013 ACR/ARHP Annual Meeting
A MORE Specific Immunoassay For The Diagnosis Of APS
Background/Purpose: Anticardiolipin (aCL) antibody assays are sensitive for the detection of antiphospholipid antibodies (aPL) in patients with the Antiphospholipid syndrome (APS) but are known to…Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta2glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…Abstract Number: 15 • 2013 ACR/ARHP Annual Meeting
Establishment Of Standardized International Units For IgM ANTI-β2glycoprotein Antibody Measurement
Background/Purpose: Recurrent IgG or IgM anti-β2glycoprotein (ab2GPI) antibody positivity is a key laboratory indicator for classification of antiphospholipid syndrome (APS). Considerable inter-laboratory variation still exists…Abstract Number: 16 • 2013 ACR/ARHP Annual Meeting
Only IgG and IgA β2glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Background/Purpose: The current APS Classification Criteria recommend testing for IgG and IgM antibodies for β2glycoprotein I (β2GPI), and do not differentiate between primary and secondary…Abstract Number: 17 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases
Background/Purpose: In the pathogenic mechanisms of antiphospholipid syndrome (APS), it is recognized that pathogenicity of antiphospholipid antibodies (aPL) has dominant effects. Complement is the part…Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…Abstract Number: L2 • 2013 ACR/ARHP Annual Meeting
Proteome-Wide Analysis and CXCL4 As a Pathogenic Biomarker in Systemic Sclerosis
Background/Purpose: We hypothesized that plasmacytoid dendritic cells are implicated in the pathogenesis of systemic sclerosis via mechanisms beyond previously suggested type I interferon production. Methods:…Abstract Number: L4 • 2013 ACR/ARHP Annual Meeting
Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 4 compared APR with placebo (PBO) in DMARD-naïve patients (pts) with…
ACR Meeting Abstracts